← All reports

GLP-1 drugs are being developed and marketed without sufficient regulatory oversight, leading to potential risks for consumers.

HealthcareLegal IssuesMay 8, 2026score 0.172 posts · 0 replies across 1 instances
The thread discusses the regulation and market dynamics of GLP-1 drugs, highlighting concerns about the lack of oversight in the wellness industry. It references articles from The New York Times and Ezra Klein podcast, emphasizing the need for better regulation and the potential risks associated with unregulated wellness products.

Claims

GLP-1 drugs are being developed and marketed without sufficient regulatory oversight, leading to potential risks for consumers.
Parent: HealthcareEntity: GLP-1 drugsImpact: negativeDate: May 8, 2026Target: GLP-1 drugs are being developed and marketed without sufficient regulatory oversight

Source posts

@[email protected]
GLP-1s and the ‘Wild West’ of Wellness https://www.nytimes.com/video/opinion/100000010875447/glp-1s-and-the-wild-west-of-wellness.html?utm_source=flipboard&utm_medium=activitypub Posted into Opinion @opinion-newyorktimes
1 boosts · 0 favs · 0 replies · May 8, 2026
@[email protected]
GLP-1s and the ‘Wild West’ of Wellness https://www.nytimes.com/2026/05/08/opinion/ezra-klein-podcast-julia-belluz.html?utm_source=flipboard&utm_medium=activitypub Posted into Opinion @opinion-newyorktimes
1 boosts · 0 favs · 0 replies · May 8, 2026